



HAL
open science

From the environment to the host: How non-azole agrochemical exposure affects the antifungal susceptibility and virulence of *Cryptococcus gattii*

Rafael Wesley Bastos, Gustavo José Cota Freitas, Hellem Cristina Silva Carneiro, Lorena Vívien Neves Oliveira, Ludmila Gouveia-Eufrasio, Anderson Philip Nonato Santos, Frederique Moyrand, Corinne Maufrais, Guilhem Janbon, Daniel Assis Santos

► **To cite this version:**

Rafael Wesley Bastos, Gustavo José Cota Freitas, Hellem Cristina Silva Carneiro, Lorena Vívien Neves Oliveira, Ludmila Gouveia-Eufrasio, et al.. From the environment to the host: How non-azole agrochemical exposure affects the antifungal susceptibility and virulence of *Cryptococcus gattii*. *Science of the Total Environment*, 2019, 681, pp.516-523. 10.1016/j.scitotenv.2019.05.094 . pasteur-02651897


HAL Id: pasteur-02651897

<https://pasteur.hal.science/pasteur-02651897>

Submitted on 11 Aug 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Highlights

- Exposure to pyraclostrobin induces cross-resistance with clinical antifungals in *Cryptococcus*
- Non-azole agrochemical exposure increases expression of efflux pumps in *C. gattii*
- Pyraclostrobin-exposed yeasts are less virulent than non-exposed ones in mice
- Fluconazole is not able to treat cryptococcosis by pyraclostrobin-exposed cells.
- Agrochemicals jeopardize animal and human health by influencing fungal resistance.

1 **From the environment to the host: how non-azole agrochemical exposure affects**
2 **the antifungal susceptibility and virulence of *Cryptococcus gattii***

3

4 Rafael Wesley Bastos^{1,2}, Gustavo José Cota Freitas¹, Hellem Cristina Silva Carneiro¹,
5 Lorena Vívien Neves de Oliveira¹, Ludmila Gouveia-Eufrásio¹, Anderson Philip Nonato
6 Santos¹, Frédérique Moyrand³, Corinne Maufrais³, Guilhem Janbon³, Daniel Assis
7 Santos^{1*}

8

9 ¹ Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal
10 de Minas Gerais, Belo Horizonte, Minas Gerais, Brasil.

11 ² Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, São
12 Paulo, Brasil.

13 ³ Département de Mycologie, Institut Pasteur, Paris, France.

14

15 *Corresponding author: Daniel Assis Santos, Departamento de Microbiologia, Instituto
16 de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Antonio Carlos,
17 6627, Pampulha, Belo Horizonte, Minas Gerais, Brazil, 31270-901. E-mail:
18 das@ufmg.br or dasufmg@gmail.com; Fax: +55 31 3409 2733.

19

20

21

22

23

24

25

26 **Abstract**

27

28 Agrochemicals such as the non-azoles, used to improve crop productivity, poses severe
29 undesirable effects on the environment and human health. In addition, they induce
30 cross-resistance (CR) with clinical drugs in pathogenic fungi. However, till date
31 emphasis has been given to the role of azoles on the induction of CR. Herein, we
32 analyzed the effect of a non-azole agrochemical, pyraclostrobin (PCT), on the
33 antifungal susceptibility and virulence of the human and animal pathogens
34 *Cryptococcus gattii* and *C. neoformans*. We determined the minimum inhibitory
35 concentration (MIC) of fluconazole (FLC), itraconazole, ravuconazole, amphotericin B,
36 and PCT on colonies: (i) that were not exposed to PCT (non adapted-NA-cultures), (ii)
37 were exposed at the maximum concentration of PCT (adapted-A-cultures) and (iii) the
38 adapted colonies after cultivation 10 times in PCT-free media (10 passages-10p-
39 cultures). Our results showed that exposure to PCT induced both temporary and
40 permanent CR to clinical azoles in a temperature-dependent manner. With the objective
41 to understand the mechanism of induction of CR through non-azoles, the transcriptomes
42 of NA and 10p cells from *C. gattii* R265 were analyzed. The transcriptomic analysis
43 showed that expression of the efflux-pump genes (*AFRI* and *MDRI*) and PCT target
44 was higher in resistant 10p cells than that in NA. Moreover, the virulence of 10p cells
45 was reduced as compared to NA cells in mice, as observed by the differential gene
46 expression analysis of genes related to ion-metabolism. Additionally, we observed that
47 FLC could not increase the survival rate of mice infected with 10p cells, confirming the
48 occurrence of permanent CR *in vivo*. The findings of the present study demonstrate that
49 the non-azole agrochemical PCT can induce permanent CR to clinical antifungals
50 through increased expression of efflux pump genes in resistant cells and that such
51 phenomenon also manifests *in vivo*.

52

53 *Keywords:* pyraclostrobin; cross-resistance; efflux pumps; fluconazole; temperature

54

55

56

57

58

59 **Introduction**

60 The growing demand for food supply has increased the consumption of
61 agrochemicals worldwide (Popp et al., 2013; Rigotto et al., 2014; Elahi et al., 2019).
62 However, their intensive use leads to severe undesirable effects on the environment
63 (Hartman et al., 2016; Cui et al., 2017) as well as human health (Rigotto et al., 2014;
64 Elahi et al., 2019). Recently, some studies have shown that agrochemicals select
65 microorganisms that are otherwise resistant to clinical antifungals, developing cross-
66 resistance (CR) (Ren et al., 2017; Brilhante et al., 2019; Bastos et al., 2018; Carneiro et
67 al., 2019). In our previous work, we showed that the triazole agrochemical tebuconazole
68 triggers permanent and temporary CR to clinical azole drugs in *Cryptococcus* spp., both
69 *in vitro* and *in vivo* (Bastos et al., 2018). Nevertheless, it is uncertain whether non-azole
70 agrochemicals such as pyraclostrobin (PCT) are also able to induce CR.

71 *Cryptococcus gattii* and *Cryptococcus neoformans* are the main etiologic agents
72 of cryptococcosis, which affect more than 200,000 people per year worldwide, with a
73 mortality rate of 81% (Rajasingham et al., 2017; Williamson et al., 2017). These
74 microorganisms are generally found in the plant habitats. More specifically, *C. gattii* is
75 found in more than 50 tree species, especially in *Eucalyptus* (Chatuverdi and
76 Chatuverdi, 2011, Prakash et al., 2018), whereas the primary niche of *C. neoformans* is
77 associated with plants as well as with birds' feces (Cogliati et al., 2016). However, it
78 remains unclear (i) how the interaction with plants influences the biology of these fungi
79 (Xue et al., 2007); and (ii) how human interferences, mainly, the use of agrochemicals
80 (Del Poeta and Casadevall, 2012), affect the biology of *Cryptococcus* spp. the way they
81 affect *Aspergillus fumigatus* (Snelders et al., 2012; Ren et al., 2017) and *Candida* spp.
82 (Brilhante et al., 2019).

83 The therapeutic arsenal used to treat cryptococcosis is composed of
84 amphotericin B (AMB), 5-flucytosine, and the azoles fluconazole (FLC) and
85 itraconazole (ITZ) (Perfect et al., 2010; Molloy et al., 2018). Despite the availability of
86 reports showing increased resistance to azoles (Smith et al., 2015; Chen et al., 2016),
87 the underlying mechanism of resistance is still unclear, especially in *C. gattii*.
88 According to previous studies, resistance may be caused by mutations in the *ERG11*
89 gene, which encodes the drug-target protein ERG11p, and also by the overexpression of
90 efflux pumps, e.g. *AFR-1* (ATP-binding cassette transporter), *AFR-2*, and *MDR11*
91 (putative ABC multidrug resistance transporter similar to Ste6) (Basso et al., 2015;
92 Yang et al., 2016, Cavalheiros et al., 2018).

93 The antifungal PCT is a strobilurin fungicide, which belongs to the quinone
94 outside inhibitors (QoI) group. QoI alters mitochondrial respiration by binding to the Qo
95 site of the cytochrome b, blocking the electron transfer to cytochrome c₁, which leads to
96 the disruption of the energy cycle (Bartlett et al., 2002). Because of its high efficiency
97 and broad-spectrum action against phytopathogenic fungi, it has been considered as an
98 “environment-friendly fungicide”. Hence, its consumption has increased worldwide
99 including in the United States, United Kingdom, and China (Bartlett et al., 2002; Oliver
100 and Hewitt, 2014; Gou et al., 2017).

101 Despite being considered low-toxic for humans, birds, mammals, and bees
102 (Barlett, 2002), there are reports of poisoning caused by PCT (CDC, 2018).
103 Furthermore, the widespread use of strobilurin fungicides, including PCT, can pose a
104 potential risk to aquatic organisms, since residues of pesticides can remain in the air,
105 soil, or water through runoff and/or leaching from soil to the surrounding waterbodies
106 (Hartman, et al., 2016; Cui, et al., 2017).

107 The present study was aimed at investigating the effect of the non-azole
108 agrochemical PCT on the susceptibility of *Cryptococcus* spp. to clinical drugs and its
109 virulence.

110

111 **Materials and Methods**

112 **Microorganisms**

113 We used twelve strains of *C. gattii* (eight clinical and two environmental
114 isolates, from the culture collection of the Laboratório de Micologia, at Universidade
115 Federal de Minas Gerais, state of Minas Gerais, Brazil; and two reference strains from
116 the culture collection of the University of Georgia, Atlanta, GA, USA) (Table 1)
117 (Santos et al., 2012). Besides four strains of *C. neoformans* (one clinical and three
118 reference strains) (Magalhães et al., 2013) were also used (Table 1). All isolates were
119 maintained in Sabouraud Dextrose Broth medium with 10% glycerol, at -80°C.

120

121 **Antifungal drug susceptibility testing**

122 The minimum inhibitory concentration (MIC) of FLC (Sigma-Aldrich, St. Louis,
123 MO), AMB (Sigma-Aldrich), and the environmental antifungal PCT (COMET[®]) were
124 determined by the microdilution method (MIC^{broth}) (CLSI, 2012). The MIC of PCT was
125 also verified by spot tests on Sabouraud Dextrose Agar (SDA) medium, supplemented
126 with different concentrations of PCT (MIC^{solid}), as previously described (Bastos et al.,
127 2018). The MIC^{broth} and MIC^{solid} tests were performed at 30°C and 35°C, and all the
128 tests were performed in duplicates for each strain.

129

130

131

132 **Agrochemical adaptation and cross-resistance tests (CR)**

133 Following MIC^{solid} tests, the strains were grown on SDA medium supplemented
134 with increasing concentrations of the pesticide. Initially, all strains were grown on a
135 medium supplemented with PCT at a concentration of MIC/2 (sub-MIC: half the MIC
136 value). After the colonies have developed, an inoculum containing approximately $1 \times$
137 10^4 to 5×10^4 fungal cells was inoculated onto SDA medium supplemented with the MIC
138 of PCT. This process was repeated, and the strains were grown in a stepwise manner, at
139 increasing amounts of PCT (ranging from 0.25 mg/L to 256.0 mg/L), up to the
140 concentration at which the growth was ceased, or until the maximum limit of 256 mg/L
141 was reached. The tests were carried out at 30°C and 35°C (Bastos et al., 2018). The
142 highest concentration of PCT at which the fungus was capable of growing after the
143 adaptation test was called Maximum Concentration Achieved (MCA). The ability of the
144 microorganisms to multiply in the presence of PCT was assessed by determining the
145 ratio between the MCA and the sub-MIC (MCA/sub-MIC).

146 The colonies exposed to the agrochemicals were named PCT-adapted (A), while
147 the original ones were called non-adapted (NA). Subsequently, the MIC^{broth} of FLC,
148 AMB, and PCT were determined for the NA and A colonies. The tests were performed
149 at two different temperatures, 30°C and 35°C (MIC^{broth} incubation temperature), for the
150 colonies adapted at 30°C temperature 35°C, respectively. The strain was considered
151 cross-resistant (CR) when it showed an increased MIC for both the agrochemical and
152 clinical drugs. The CR was further classified either as temporary or permanent
153 depending on the restoration of susceptibility to the drugs. In temporary CR the
154 agrochemical-adapted colonies returned to their original susceptibility and the colonies
155 showing permanent CR stayed susceptible to the drugs even after the withdrawal of
156 PCT for 10 passages (10p colonies) (Bastos et al., 2018).

157 We also tested the CR between PCT and ITZ (Sigma-Aldrich), and between
158 PCT and ravuconazole (RVZ; Sigma-Aldrich) in PCT-adapted and 10p colonies that
159 showed CR to FLC.

160

161 **Transcriptome analysis**

162 NA and 10p cells of *C. gattii* R265 (that demonstrated permanent CR) were
163 grown in a YPD medium without the drugs at 30°C, for total RNA extraction (Moyrand
164 et al., 2008), in triplicates. For sequencing, strand-specific paired-end cDNA libraries
165 were prepared from 10 µg of total RNA, by using the Illumina mRNA-Seq-Sample Prep
166 Kit, according to the manufacturer's instructions. cDNA fragments of ~400 bp from
167 each library were purified and checked for their quality using a Bioanalyzer (Agilent),
168 followed by sequencing of 100 bp fragments from both ends using an Illumina
169 HiSeq2000 instrument. The differential gene expression was investigated using DESeq1
170 v1.1659, DESeq2 v1.4.160, and edgeR v3.6.161, with default settings and false
171 discovery rate (FDR) cutoff set at 0.05. The genes with more than 10 mapped fragments
172 in at least one library were selected, and the fold change output from DESeq2 was
173 considered as the decisive fold change. A gene was considered significantly
174 differentially expressed when the fold change was higher or lower than 1.5.

175

176 ***In vivo* tests**

177 C57BL/6 male mice, aged 6-8 weeks, were used. All experimental procedures
178 were carried out according to the standards of the Brazilian Society of Laboratory
179 Animal Science/Brazilian College for Animal Experimentation
180 (<http://www.sbcal.org.br>). The study was approved by the Ethics Committee in Animal

181 Experimentation of the Universidade Federal de Minas Gerais (CEUA/UFMG, protocol
182 number 306/2015).

183 The animals (n=6) were anesthetized with ketamine (60mg/kg) and xylazine
184 (10mg/kg), followed by infection with 1×10^5 non-adapted or 10p (30°C) *C. gattii* R265
185 cells through the intratracheal route. Some groups were treated daily with 20 mg/kg of
186 FLC through the intraperitoneal route (the controls are represented by the untreated
187 groups). The mice were monitored daily for survival (Ferreira et al., 2015). Further,
188 other groups of mice were also infected with NA and 10p cells and the animals were
189 anesthetized and euthanized after 15 days to collect the lungs. The lungs were then
190 homogenized in phosphate buffered saline (PBS), and plated on SDA medium. After
191 48h of incubation at 35°C, the recovered colonies were collected and subsequently used
192 for the MIC^{broth} test.

193

194 **Statistical analysis**

195 All statistical analysis, except for the transcriptome data, was performed with the
196 software GraphPad Prism, version 6.00 for Windows (GraphPad Software, San Diego,
197 CA, USA). The significance test was done by Student's t-test at $p < 0.05$. The survival
198 curve was plotted according to Kaplan-Meier analysis, and the results were examined
199 using the log-rank test. All analyses were repeated at least twice.

200

201

202

203

204

205

206 **Results**

207 **Adaptation process increases resistance to PCT**

208 Initially, we determined the MIC of FLC, AMB, and PCT for each strain of
209 *C.gattii* and *C. neoformans* at 30°C and 35°C. The results showed inhibition of all the
210 strains by the drugs when the MIC was checked in the broth medium (MIC^{broth}) (data
211 not shown) and solid medium (MIC^{solid}) (Table 1).

212 MIC^{solid} test revealed that all strains of *C. gattii* and *C. neoformans* were capable
213 of growth at higher concentrations of PCT when the adaptation test was performed at
214 30°C (Table 1), of which, *C. gattii* L27/01 tolerated the agrochemical the most in the
215 adaptation test, being able to grow in a medium 2,048 times richer in PCT (Table 1).
216 However, the adaptation test at 35°C revealed that 75% of the *C. gattii* and 100% of the
217 *C. neoformans* strains tolerated more the PCT (Table 1).

218 The geometric means of the ratio MCA/Sub-MIC at 30°C were observed to be
219 higher than those at 35°C in both the species (Table 1), indicating the influence of the
220 temperature on adaptation.

221

222 **PCT exposure causes temporary and permanent cross-resistance with clinical** 223 **azolesin a temperature-dependent manner**

224 An increase (more than four folds) in the MIC of PCT was observed in 58.3%
225 (n=7) of the *C. gattii* strains and 100% (n=4) of the *C. neoformans* (Tables 2 and 3)
226 after the adaptation process at 30°C. However, the MIC^{broth} tests performed at 35°C
227 identified only five strains of *C. gattii*, demonstrating less susceptibility to the pesticide.
228 Further, all PCT-adapted colonies of *C. neoformans* adapted at 30°C were independent
229 of the temperature variations (Table 3).

230 Furthermore, we tested whether the PCT exposure had affected the susceptibility
231 of the pathogens to FLC and AMB. Tables 2 and 3 show that the geometric mean values
232 of FLC MIC^{broth} for PCT-adapted cells at 30°C increased by more than 2.0 times for *C.*
233 *gattii*. On the other hand, the geometric means of adapted cells did not differ
234 considerably from those of NA cells (Tables 2 and 3) at 35°C for *C. gattii*, and at both
235 temperatures for *C. neoformans*. It was observed that 41.6% (n=5) of the *C. gattii* and
236 25% (n=1) of the *C. neoformans* strains presented CR to FLC when the adaptation and
237 MIC processes were performed at 30°C (Tables 2 to 4). Four (33.3%) *C. gattii* strains
238 (R265, ATCC 24065, L24/01, and L27/01) demonstrated permanent CR, and did not
239 return to their original susceptibility even after growing them for 10 passages in an
240 agrochemical-free media (Tables 2 and 4). In contrast, three strains of *C. gattii* and one
241 strain of *C. neoformans* (ATCC 62066) exhibited a temporary CR by returning to their
242 original susceptibility after 10 passages in a medium without PCT (Tables 2to4). The
243 permanent and temporary CR displayed by *C. gattii* R265 and 547/OTTI/94-PI-10,
244 respectively, were verified both at 30°C and 35°C (Table 2). The PCT-adapted cells at
245 30°C that exhibited CR to FLC were also found to show CR to RVZ (Table 5), but not
246 to ITZ (Table 5) and AMB (data not shown).

247 Additionally, the adaptation test at 35°C identified higher MIC^{broth} of PCT for
248 two strains of *C. gattii* and one of *C. neoformans* (Table 6). However, a CR to FLC
249 (Tables 4 and 6) and AMB (data not shown) was not observed.

250

251 **Transcriptomic profile of *C. gattii* R265 10p cells is different from that of NA cells.**

252 To investigate the permanent changes caused by the PCT exposure, we
253 compared the RNA expression profile in NA and 10p cells of *C. gattii* R265. Both the
254 cells were grown in a medium without PCT, at 30°C. The analysis identified 230 genes

255 showing differential expression, of which 110 were up-regulated and 120 were down-
256 regulated. Though most of these genes encode hypothetical proteins (55.2%), the genes
257 related to amino acid metabolism, oxidation-reduction process, sugar metabolism,
258 transmembrane transport, nucleotide metabolism, ribosome biogenesis, drug transport,
259 cell wall biosynthesis, and phosphatases were up-regulated in the 10p cells than the NA
260 cells (Figure 1A). However, the down-regulated genes were related to the amino acid,
261 sugar and ion metabolism, oxidation-reduction process, membrane component,
262 transmembrane transport, and RNA metabolism (Figure 1B).

263 The genes like *CTR4* [solute carrier family 31 (copper transporter), member 1]
264 and *FRE* (ferric-chelate reductase)-1 and 7, probably involved in virulence of
265 *Cryptococcus* spp. were also down-regulated (Table 7).

266

267 **Efflux pumps and genes encoding PCT target were up-regulated in 10p cells**

268 It has been proposed that *Cryptococcus* spp. becomes less susceptible to azole
269 drugs due to the overexpression of *ERG-11* and/or efflux-pumps genes (*AFR-1*, *AFR-2*,
270 and *MDR11*) (Basso et al., 2015; Bastos et al., 2018). We searched for the genes
271 mentioned above in the transcriptome data, to validate their role in the development of
272 resistance to azoles. We found that *AFR1* and *MDR11* were up-regulated (1.5 times fold
273 change) in the 10p cells (Table 7), suggesting their role in the development of the
274 observed phenotype. Though, we did not observe any significant difference in the
275 expression profile of *ERG11*, *CNBG_4400*, the gene encoding cytochrome b2, the target
276 for the agrochemical PCT, was more expressed (2.05 times fold change) in the 10p cells
277 (Table 7).

278

279 ***C. gattii* R265 10p cells are less virulent and more resistant to FLC than NA cells *in***
280 ***vivo***

281 For *in vivo* validation of the reduced virulence in the 10p cells, both NA and 10p
282 cells of *C. gattii* R265 were tested in mice. All animals infected with NA cells died
283 within 30 days of post-infection (d.p.i). On the other hand, 20% of the mice infected
284 with 10p cells were alive 60 d.p.i. revealing their lower virulence ($p < 0.05$) (Figure 2).

285 It was observed that the treatment with FLC increased the survival rate of NA-
286 infected mice, as they remained alive even after 60 d.p.i. In contrast, FLC could not
287 augment the survival of the mice infected with 10p cells (Figure 1), demonstrating the
288 *in vivo* occurrence of CR.

289 In addition, we tested the MIC^{broth} for colonies recovered from the lungs of mice
290 infected with NA and 10p cells for 15 days. The colonies from animals infected with
291 10p cells were less susceptible to PCT and all the clinical azoles tested than the NA
292 colonies (Figure1), indicating that the 10p cells of *C. gattii* R265 present *in vivo* CR to
293 FLC and other azole drugs.

294

295 **Discussion**

296 The fast-growing world population calls for increasing food supply, thereby
297 increased crop productivity. In order to achieve this, the use of agrochemicals is the
298 most preferred alternative that helps to avoid losses due to pests such as insects and
299 microorganism infections (Popp et al., 2013). However, these substances may pose
300 harmful effects on human and animal health and the environment (Rigotto et al., 2014).
301 Recently, we showed that tebuconazole, an environmental triazole, causes temporary
302 and permanent CR to clinical azoles in *C. gattii* and *C. neoformans* (Bastos et al., 2018).
303 However, it is not well-understood whether non-azole agrochemicals induce the same

304 effect. In this work, we showed that the agrochemical PCT, which inhibits the activity
305 of the cytochrome b and the electron transport chain in mitochondria, is also able to
306 select cells of *Cryptococcus* that are less susceptible to azole drugs (FLC, ITZ, and
307 RVZ). PCT was chosen for this study for several reasons, including its action
308 mechanism (non-azole), extensive use (Bartlett et al., 2002; Oliver and Hewitt, 2014;
309 Gou et al., 2017), and broad-spectrum activity. It has also been reported to be used for
310 *Eucalyptus* habitats, where *Cryptococcus* spp. can be found (Chatuverdi and
311 Chatuverdi, 2011).

312 Temperature is a crucial factor that controls the growth of *Cryptococcus*. Several
313 studies have reported its involvement in several phenomena such as the generation of
314 titan cells, hyphal growth, inheritance patterns of mitochondria, capsule size, survival
315 inside avian macrophages, and general virulence (Zaragoza and Casadevall, 2004;
316 Bielska and May, 2015; Wang et al., 2015; Johnston et al. 2017; and Watkins et al.,
317 2017; Hommel et al., 2018). In the present study, we observed that the rate of CR is
318 dependent on the temperature at which the adaptation test was conducted. When the test
319 was carried out at 30°C, more strains of *C. gattii* and *C. neoformans* presented CR to
320 FLC. Additionally, the lowest temperature positively influenced the concentration of
321 PCT tolerated by the fungi. Our results show the capacity of acquiring mechanisms
322 related to CR between agrochemical and azole clinical drugs, thus supporting the earlier
323 findings. Besides, the incubation temperature during the MIC^{broth} tests was also relevant
324 to the CR exhibited by the strains adapted at 30°C. While some strains presented CR to
325 FLC, regardless of the incubation temperature, others showed increased resistance only
326 when the cells were incubated at 30°C. These results reinforce that even with higher
327 resistance in the environment at low temperatures, resistance may not manifest in
328 animal infections due to the mammalian body temperature (Bastos et al., 2018).

329 While PCT targets the mitochondrial metabolism, azole drugs act on the
330 ergosterol synthesis. Therefore, the next question was why the cells that had been
331 exposed to the non-azole agrochemical became less susceptible to clinical azoles.
332 Association between mitochondrial metabolism deficiency and azole resistance in
333 *Cryptococcus* has been poorly documented. Nevertheless, it has been described that *C.*
334 *neoformans* becomes less susceptible to FLC when brought into contact with
335 tetracycline, an antibiotic that interferes in the synthesis of bacterial and mitochondrial
336 proteins (Oliver et al., 2008).

337 In an attempt to better understand why PCT-exposed cells become less
338 susceptible to clinical azoles, we performed the transcriptome analysis of the NA and
339 10p cultures of *C. gattii* R265, which had presented permanent CR to these drugs. The
340 upregulation of efflux-pump genes, *AFRI*, and *MDRI* in 10p cells demonstrated a
341 hypothesis for the underlying mechanism for the development of azole resistance in 10p
342 cells. It could be because of pumping out of the antifungal drugs out of the cell.
343 However, it is still not clear, whether or not PCT is also pumped out by the efflux
344 pumps of *Cryptococcus* spp.

345 Another well-documented mechanism of resistance to PCT in environmental
346 fungi involves mutations in the gene encoding the drug target, *cytb* (cytochrome b) (Yin
347 et al., 2012). In our work, 10p cells were able to express 2-fold more Cytb than NA
348 cells, which may be the cause of the less susceptible phenotype.

349 *Cryptococcus* spp. have several virulence factors, being the following the classic
350 ones: capsule production, ability to grow at 37°C, and production of enzymes, among
351 them phospholipase, urease, laccase, and SOD (Bielska and May, 2015). Recently, other
352 important virulence pathways of this genus have been studied, which include the
353 obtention and use of metals, like iron, copper, and zinc. These ions act as cofactors of

354 several enzymes, and they are essential in processes like respiration. Because of their
355 importance, microorganisms like *Cryptococcus* must be able to acquire them from the
356 environment and from the host to ensure their growth (Silva et al., 2011). In this
357 context, we identified that the gene *CTR4* and other possible genes involved in ion
358 metabolism were less expressed in the 10p cells. CTR4p is a copper-transport protein,
359 essential not only for copper homeostasis but also for the virulence of *C. neoformans*,
360 since a *ctr4Δ* strain is less virulent than the corresponding wild type (Waterman et
361 al., 2012). Thus, we hypothesize that low expression of the genes related to iron and
362 copper obtention may lead to reduced virulence in the 10p cells. The less virulent
363 phenotype was further confirmed in the mice model.

364 Finally, to investigate if the drug resistance observed *in vitro* also manifests *in*
365 *vivo*, we infected the mice with NA and 10p cells of *C. gattii* R265 that presented CR to
366 all clinical azoles. We then treated some of the animals with FLC, while others were
367 kept untreated as the control. The treatment with the drug did not change the survival of
368 the animals infected with the 10p cells, as opposed to the mice infected with NA cells.
369 *In vivo* CR was also confirmed in colonies recovered from the lungs of animals infected
370 with 10p cells. They were less susceptible to PCT and azoles than those obtained from
371 animals infected with NA cells.

372 **Conclusion**

373 In conclusion, fungicide PCT exposure selects cells with CR to clinical azole
374 drugs, both *in vitro* and *in vivo*. PCT also decreased the virulence of *C. gattii* R265,
375 after contact with the agrochemical ceased. This study demonstrates the permanent
376 implications of non-azole agrochemicals on fungal virulence and susceptibility to drugs
377 and indicates how anthropic action in the environment could be responsible for the
378 evolution of resistant strains of *Cryptococcus* spp.

379 **Funding**

380 This study was supported by Fundação de Amparo a Pesquisa do Estado de
381 Minas Gerais - FAPEMIG (Grant APQ-00727-16 and PPM-00061-18) and Conselho
382 Nacional de Desenvolvimento Científico e Tecnológico - CNPq (Grants 403006/2016-3
383 and 440010/2018-7). RWB received fellowships from CNPq and Coordenação de
384 Aperfeiçoamento de Pessoal de Nível Superior (PDSE-CAPES -88881.131683/2016-
385 01). DAS is a research fellow of the CNPq (Grant 302670/2017-3).

386 We declare that we have no conflicts of interest.

387

388 **Transparency declarations.**

389 None to declare.

390

391

392 **Author contributions**

393 Conceived and designed the experiments: RWB, DAS, GJ. Performed the experiments:
394 RWB, GJCF, HCSC, LVNO, LGE, APNS, FM. Analyzed the data: RWB, CM, DAS.
395 Contributed reagents/materials/analysis tools: GJ, DAS. Contributed to the writing of
396 the manuscript: RWB, GJ, DAS.

397

398 **Legends of the figures:**

399 **Figure 1:** Transcriptomic profile of *C. gattii* R265 adapted cells grown in medium
400 without pyraclostrobin (PCT) (10p) and non-adapted (NA) cells. The function of genes
401 (A) up- and (B) down-regulated in 10p cells compared to NA.

402

403 **Figure 2:** Virulence and *in vivo* cross-resistance in non-adapted (NA) and adapted cells
404 grown in medium without agrochemical (10p). (A) 10p cells are significantly ($p<0.05$)
405 less virulent than NA. The treatment with fluconazole (FLC) significantly ($p<0.05$)
406 increased the survival of mice infected with NA, but not of those infected with 10p
407 cells. (B) Cells recovered from the lungs of animals infected with 10p colonies were
408 more resistant to pyraclostrobin (PCT), FLC, itraconazole (ITZ) and ravuconazole
409 (RVZ), but not to amphotericin B (AMB) than those recovered from NA-infected mice.
410 * $p<0.05$; ** $p<0.01$.

411

412 **References**

413

- 414 BIELSKA, E; MAY, R. C. What makes *Cryptococcus gattii* a pathogen? **FEMS Yeast**
415 **Res**, v. 16, n. 1, p. fov106, 2016.
- 416 BARTLETT, D. W. *et al.* The strobilurin fungicides. **Pest Manag Sci**, v. 58, n. 7, p.
417 649-62, 2002.
- 418 BASSO, L. R. *et al.* Identification and properties of plasma membrane azole efflux
419 pumps from the pathogenic fungi *Cryptococcus gattii* and *Cryptococcus neoformans*. **J**
420 **Antimicrob Chemother**, v. 70, n. 5, p. 1396-407, 2015.
- 421 BASTOS R. W. *et al.*. 2018. Environmental triazole induces crossresistance to clinical
422 drugs and affects morphophysiology and virulence of *Cryptococcus gattii* and *C.*
423 *neoformans*. **Antimicrob Agents Chemother** 62:e01179-17, 2018.
- 424 BRILHANTE, R. S. N. *et al.* Exposure of *Candida parapsilosis* complex to agricultural
425 azoles: an overview of the role of environmental determinants for the development of
426 resistance. **Sci Total Environ**, v.650(Pt 1), p. 1231-1238, 2019.
- 427 CAVALHEIROS *et al.*, 2018. Host-pathogen interactions mediated by *mdr* transporters
428 in fungi: as pleiotropic as it gets!**Genes (Basel)**. V. 9, n. 7, pii: E332.
- 429 CDC (Centers for Disease Control and Prevention). Acute pesticide poisoning
430 associated with pyraclostrobin fungicide-Iowa, 2007. **MMWR Morb Mortal Wkly Rep**
431 v. 56 (51–52):1343–5, 2008.
- 432 CHATURVEDI, V.; CHATURVEDI, S. *Cryptococcus gattii*: a resurgent fungal
433 pathogen. **Trends Microbiol**, v. 19, n. 11, p. 564-71, 2011.
- 434 CHEN, Y. C, *et al.* Increasing trend of fluconazole-non-susceptible *Cryptococcus*
435 *neoformans* in patients with invasive cryptococcosis: a 12-year longitudinal study.
436 **BMC Infect Dis**, v.15, n.277, p. 1-7. 2015.

437 **CLINICAL AND LABORATORY STANDARDS INSTITUTE.** Reference method
438 for broth dilution antifungal susceptibility testing of yeasts: fourth informational
439 supplement, CLSI document M27- S4. Clinical and Laboratory Standards Institute,
440 Wayne, PA, 2012.

441 COGLIATI, M. *et al.* Environmental distribution of *Cryptococcus neoformans* and *C.*
442 *gattii* around the Mediterranean basin. **FEMS Yeast Res**, v. 16: pii: fow045, 2016.

443 CUI, F, et al. Toxicity of three strobilurins (kresoxim-methyl, pyraclostrobin, and
444 trifloxystrobin) on *Daphnia magna*. **Environmental Toxicology and Chemistry**, vol.
445 36, n. 1, p. 182–9, 2017.

446 DEL POETA, M.; CASADEVALL A. Ten challenges on *Cryptococcus* and
447 cryptococcosis. **Mycopathologia**, v. 173, p. 303–10, 2012.

448 ELAHI, E, *et al.* Agricultural intensification and damages to human health in relation to
449 agrochemicals: Application of artificial intelligence. **Land Use Policy**, v. 83, p. 461-
450 474, 2019.

451 FERREIRA, G. F, *et al.* Heteroresistance to Itraconazole Alters the Morphology and
452 Increases the Virulence of *Cryptococcus gattii*. **Antimicrob Agents Chemother**, v. 59,
453 n. 8, p. 4600-9, 2015.

454 GUO, X. *et al.* Residue dynamics and risk assessment of pyraclostrobin in rice, plants,
455 hulls, field soil, and paddy water. **Human and Ecological Risk Assessment: An**
456 **International Journal**, v. 23, n.1, p. 67-81, 2017.

457 HARTMAN, E. A. *et al.* Chronic effects of strobilurin fungicides on development,
458 growth, and mortality of larval Great Plains toads (*Bufo cognatus*). **Ecotoxicology** v.
459 23, p. 396-403, 2014.

460 HOMMEL, B. *et al.* Titan cells formation in *Cryptococcus neoformans* is finely tuned
461 by environmental conditions and modulated by positive and negative genetic regulators.
462 **PLoS Pathog**, v. 14, n.5: e1006982, 2018.

463 JOHNSTON, S. A.; VOELZ, K.; MAY, R. C. *Cryptococcus neoformans*
464 thermotolerance to avian body temperature is sufficient for extracellular growth but not
465 intracellular survival in macrophages. **Sci Rep**, v. 6, 20977, 2016.

466 MAGALHÃES, T. F. *et al* Hydroxyaldimines as potent in vitro anticryptococcal agents.
467 **Lett Appl Microbiol**, v. 57, p. 137-143, 2013.

468 MOLLOY, S. F. *et al.* Antifungal combinations for treatment of cryptococcal
469 meningitis in africa. **N Engl J Med**, v. 378, n. 11, p. 1004-1017, 2018.

470 MOYRAND, F. *et al.* UGE1 and UGE2 regulate the UDP-glucose/UDP-galactose
471 equilibrium in *Cryptococcus neoformans*. **Eukaryot Cell**, v. 7, p. 2069-77, 2008.

472 OLIVER. B. G., *et al.* Tetracycline alters drug susceptibility in *Candida albicans* and
473 other pathogenic fungi. **Microbiology**, v. 154, p. 960-970, 2008.

474 OLIVER, R. P. , HEWITT HG. Fungicides in crop protection. 2. CABI, 2014.

475 PERFECT, J. R. *et al.* Clinical practice guidelines for the management of cryptococcal
476 disease: 2010 update by the infectious diseases society of america. **Clin Infect Dis**, v.
477 50, n. 3, p. 291-322, 2010.

478 PRAKASH A. *et al.* Environmental distribution of *Cryptococcus* species and some
479 other yeast-like fungi in India. **Mycoses**. V. 61, n. 5, p. 305- 13, 2018.

480 POPP, J. *et al.* Pesticide productivity and food security: a review. **Agron Sustain Dev**,
481 v. 34, n. 1, p. 243-55, 2013. PRAKASH A., *et al.* Environmental distribution of
482 *Cryptococcus* species and some other yeast-like fungi in India. **Mycoses**. V. 61, n. 5, p:
483 305- 13, 2018.

484 RAJASINGHAM, R. *et al.* Global Burden of Disease of HIV-Associated Cryptococcal
485 Meningitis: An Updated Analysis. **Lancet Infect. Dis**, v. 3099, p. 1-9, 2017.

486 REN, J. *et al.* Fungicides induced triazole-resistance in *Aspergillus fumigatus* associated
487 with mutations of TR46/Y121F/T289A and its appearance in agricultural fields.**J**
488 **Hazard Mater**. v. 326, p. 54-60, 2017.

489 RIGOTTO, R. M.; VASCONCELOS, D. P.; ROCHA, M. M. Pesticide use in Brazil
490 and problems for public health. **Cad Saude Publica**, v. 30, n. 7, p. 1360-2, 2014.

491 SANTOS, J. R. *et al.* Dynamic interaction between fluconazole and amphotericin B
492 against *Cryptococcus gattii*. **Antimicrob Agents Chemother**, v. 56, n. 5, p. 2553-8,
493 2012

494 SILVA, M. G. *et al.* The homeostasis of iron, copper, and zinc in *Paracoccidioides*
495 *brasiliensis*, *Cryptococcus neoformans* var. *grubii*, and *Cryptococcus gattii*: a
496 comparative analysis. **Front Microbiol**, 2:49, 2011.

497 SMITH, K. D. *et al.* Increased Antifungal Drug Resistance in Clinical Isolates of
498 *Cryptococcus neoformans* in Uganda. **Antimicrob Agents Chemother**, v. 59, n. 12, p.
499 7197-204, 2015.

500 SNELDERS, E. *et al.* Triazole fungicides can induce cross-resistance to medical
501 triazoles in *Aspergillus fumigatus*. **PLoS One**, v. 7, n. 3, p. e31801, 2012.

502 XUE, C. *et al.* The human fungal pathogen *Cryptococcus* can complete its sexual cycle
503 during a pathogenic association with plants. **Cell Host Microbe**, v. 1, n. 4, p. 263-73,
504 2007.

505 WANG, Z.; WILSON, A.; XU, J. Mitochondrial DNA inheritance in the human fungal
506 pathogen *Cryptococcus gattii*. **Fungal Genet Biol**, v. 75, p. 1-10, 2015.

507 WATERMAN, S. R. *et al.* Role of CTR4 in the virulence of *Cryptococcus neoformans*.
508 **mBio**, v. 3, n. 5, e00285-12, 2012.

509 WATKINS, R. A; KING, J. S.; JOHNSTON, S. A. Nutritional requirements and their
510 importance for virulence of pathogenic *Cryptococcus* species. **Microorganisms**. v. 5,
511 n.4, p. 1-20, 2017.

512 WILLIAMSON, P. R. *et al.* Cryptococcal meningitis: epidemiology, immunology,
513 diagnosis and therapy. **Nat Rev Neurol**, v. 13, n. 1, p. 13-24, 2017.

514 YANG, M. L. *et al.* Fluconazole Susceptibility in *Cryptococcus gattii* Is Dependent on
515 the ABC Transporter Pdr11. **Antimicrob Agents Chemother**, v. 60, n. 3, p. 1202-7,
516 2016.

517 YIN, Y. N. *et al.* Molecular characterization of pyraclostrobin resistance and structural
518 diversity of the cytochrome b gene in *Botrytis cinerea* from apple. **Phytopathology**, v.
519 102, n. 3, p. 315-22, 2012.

520 ZARAGOZA, O.; CASADEVALL A. Experimental modulation of capsule size in
521 *Cryptococcus neoformans*. **Biol Proced Onli**

Table 1. Screening of subpopulations of *C. gattii* and *C. neoformans* strains less susceptible to pyraclostrobin (PCT-adaptation).

Strain or parameter	MIC ^{solid} (mg/L)		MCA (mg/L)		MCA/Sub-MIC ^{solid}	
	30°C	35°C	30°C	35°C	30°C	35°C
<i>C. gattii</i>						
R265 (C)	1.0	1.0	200.0	1.0	400.0	2.0
ATCC 24065 (R)	1.0	0.5	256.0	1.0	512.0	4.0
ATCC 32608 (R)	1.0	0.5	10.0	1.0	20.0	4.0
547/OTTI/94-PI-10 (E)	1.0	0.5	1.0	1.0	2.0	4.0
ICB 181 (E)	1.0	1.0	10.0	0.5	20.0	2.0
L24/01 (C)	1.0	1.0	1.0	0.5	2.0	2.0
L27/01 (C)	0.25	0.25	256.0	0.5	2,048.0	4.0
L28/02 (C)	0.25	1.0	0.5	0.5	4.0	1.0
1913/ER (C)	1.0	2.0	256.0	256.0	512.0	256.0
LMM 818 (C)	2.0	2.0	256.0	1.0	256.0	1.0
23/10893 (C)	1.0	2.0	12.0	1.0	24.0	1.0
29/10893 (C)	1.0	2.0	256.0	175.0	512.0	175.0
Range	0.25 – 2.0	0.25 – 2.0	1.0 – 256.0	1.0 – 256.0	2.0 – 2,048.0	1.0 – 256.0
Geometric mean	0.84	0.94	26.71	1.93	63.63	4.60
<i>C. neoformans</i>						
H99 (C)	1.0	1.0	2.0	2.0	4.0	4.0
ATCC 24067 (R)	0.5	2.0	2.0	2.0	8.0	2.0
ATCC 28957 (R)	1.0	2.0	10.0	2.0	20.0	2.0
ATCC 62066 (R)	1.0	2.0	2.0	2.0	4.0	2.0
Range	0.5 – 1.0	1.0 – 2.0	2.0 – 10.0	2.0	4.0 – 20.0	2.0 – 4.0
Geometric mean	0.84	1.68	2.99	2.0	7.11	2.38

MIC^{solid}: Minimum Inhibitory Concentration of pyraclostrobin on a solid medium, before the adaptation process. MCA: Maximum Concentration Achieved by pyraclostrobin in the PCT-adaptation test. C: clinical strain; R: reference strain; E: environmental strain.

Table 2. Minimum inhibitory concentrations (MICs.mg/L) of fluconazole and pyraclostrobin for non-adapted (NA) cells of *C. gattii* strains .PCT-adapted (A) at 30°C and PCT-adapted colonies subcultured 10 times in agrochemical-free medium (10p - 10 passages). Tests were performed at 30°C and 35°C.

Strain or parameter	Fluconazole ^a						Pyraclostrobin ^b					
	Temperature 30°C			Temperature 35°C			Temperature 30°C			Temperature 35°C		
	NA	A	10p	NA	A	10p	NA	A	10p	NA	A	10p
R265	8.0	128.0 (16X)	128.0 (16X)	8.0	32.0 (4X)	32.0 (4X)	1.0	16.0 (16X)	8.0 (16X)	0.5	2.0 (4X)	2.0 (4X)
ATCC 24065	4.0	16.0 (4X)	16.0 (4X)	4.0	4.0	ND	0.125	1.0 (8X)	1.0 (8X)	0.125	1.0 (8X)	1.0 (8X)
ATCC 32608	16.0	32.0	ND	8.0	16.0	ND	2.0	4.0	ND	1.0	2.0	ND
547/OTTI/94-PI-10	16.0	128.0 (8X)	16.0	8.0	32.0 (4X)	8.0	1.0	8.0 (8X)	1.0	1.0	4.0 (4X)	1.0
ICB 181	16.0	16.0	ND	8.0	16.0	ND	0.5	4.0 (8X)	4.0 (8X)	0.25	1.0 (4X)	2.0 (8X)
L24/01	16.0	64.0 (4X)	64.0 (4X)	8.0	16.0	ND	0.25	1.0 (4X)	2.0 (8X)	0.25	1.0 (4X)	2.0 (8X)
L27/01	16.0	64.0 (4X)	64.0 (4X)	32.0	16.0	ND	1.0	128.0 (128X)	4.0 (4X)	2.0	1.0	ND
L28/02	32.0	64.0	ND	16.0	32.0	ND	1.0	1.0	ND	0.5	1.0	ND
1913/ER	16.0	32.0	ND	16.0	8.0	ND	8.0	8.0	ND	1.0	2.0	ND
LMM 818	16.0	16.0	ND	16.0	8.0	ND	8.0	8.0	ND	2.0	4.0	ND
23/10893	8.0	4.0	ND	8.0	4.0	ND	4.0	4.0	ND	4.0	4.0	ND
29/10933	8.0	16.0	ND	4.0	4.0	ND	4.0	128.0 (32X)	128.0 (32X)	4.0	4.0	ND
MIC range	4.0 – 32.0	4.0 – 128.0	ND	4.0 – 32.0	4.0 – 32.0	ND	0.125 – 8.0	1.0 – 128.0	ND	0.125 – 4.0	1.0 – 4.0	ND
Geometric mean	12.70	28.50	ND	9.51	11.98	ND	1.33	6.72	ND	0.84	1.88	ND

a: MIC endpoint considering 50% of growth inhibition; *b*: MIC endpoint considering 100% of growth inhibition. The number in parentheses shows how many times (X) the MIC value of the PCT-adapted or 10p colonies was higher ($\geq 4X$) than the MIC of the NA colonies. Values in bold indicate an increase in the MIC by at least 4X more than in the NA colonies. ND = not determined.

Table 3. Minimum inhibitory concentrations (MICs.mg/L) of fluconazole and pyraclostrobin for non-adapted (NA) cells, PCT-adapted (A) at 30°C and PCT-adapted colonies subcultured 10 times in agrochemical-free medium (10p - 10 passages) of *C. neoformans* strains. Tests were performed at 30°C and 35°C.

Strain or parameter	Fluconazole ^a						Pyraclostrobin ^b					
	Temperature 30 °C			Temperature 35 °C			Temperature 30 °C			Temperature 35 °C		
	NA	A	10p	NA	A	10p	NA	A	10p	NA	A	10p
H99	16.0	16.0	ND	8.0	8.0	ND	0.5	128.0 (256X)	8.0 (16X)	0.5	2.0 (4X)	2.0 (4X)
ATCC 24067	16.0	8.0	ND	4.0	2.0	ND	2.0	128.0 (64X)	128.0 (64X)	1.0	128.0 (128X)	32.0 (32X)
ATCC 28957	4.0	8.0	ND	2.0	2.0	ND	0.5	8.0 (16X)	4.0 (8X)	0.25	1.0 (4X)	2.0 (8X)
ATCC 62066	4.0	16.0 (4X)	8.0	4.0	4.0	ND	1.0	8.0 (4X)	2.0	1.0	4.0 (4X)	2.0
MIC range	4.0 - 16.0	8.0 – 16.0	ND	2.0 - 8.0	2.0 - 8.0	ND	0.25 - 1.0	8.0 - 128.0	ND	0.25 - 1.0	1.0 - 128.0	ND
Geometric mean	8.0	11.31	ND	4.0	3.36	ND	0.84	32.0	ND	0.59	5.65	ND

a: MIC endpoint considering 50% of growth inhibition; *b*: MIC endpoint considering 100% of growth inhibition. The number in parentheses shows how many times (X) the MIC value of the PCT-adapted or 10p colonies was higher ($\geq 4X$) than the MIC of the NA colonies. Values in bold indicate an increase in the MIC by at least 4X more than in the NA colonies. ND = not determined.

Table 4. Percentage (%) of cross-resistance (CR) between PCT and FLC presented by *C. gattii* and *C. neoformans* strains after PCT-adaptation at 30 °C and 35°C.

Resistance	<i>C. gattii</i>		<i>C. neoformans</i>	
	30°C	35°C	30°C	35°C
Cross- resistance (CR)	41.6	0	25	0
Temporary CR	8.3	0	25	0
Permanent CR	33.3	0	0	0

Table 5. Minimum inhibitory concentrations (MICs.mg/L) of itraconazole and ravuconazole for non-adapted (NA) cells of *C. gattii* and *C. neoformans* strains. PCT-adapted (A) at 30°C and PCT-adapted colonies subcultured 10 times in agrochemical-free medium (10p-10 passages). Tests were performed at 30°C and 35°C.

Strain	Itraconazole ^a						Ravuconazole ^a					
	Temperature 30°C			Temperature 35°C			Temperature 30°C			Temperature 35°C		
	NA	A	10p	NA	A	10p	NA	A	10p	NA	A	10p
<i>C. gattii</i>												
R265	0.5	1.0	1.0	0.25	0.25	0.5	0.125	2.0 (16X)	2.0 (16X)	0.03	0.12 (4X)	0.12 (4X)
ATCC 24065	0.5	1.0	0.5	0.25	0.5	0.5	0.06	0.25 (4X)	0.125	0.03	0.12 (4X)	0.03
547/OTTI/94-PI-10	0.5	1.0	ND	0.25	0.5	ND	0.25	1.0 (4X)	ND	0.06	0.25 (4X)	ND
L24/01	1.0	1.0	1.0	0.5	1.0	1.0	0.125	1.0 (8X)	1.0 (8X)	0.06	0.5 (8X)	0.25 (4X)
L27/01	0.25	0.25	0.5	0.25	0.25	0.25	0.125	0.5 (4X)	0.5 (4X)	0.03	0.25 (4X)	0.25 (4X)
<i>C. neoformans</i>												
ATCC 62066	0.25	0.5	ND	0.25	0.5	ND	0.03	0.5 (16X)	ND	0.031	0.12 (4X)	ND

a: MIC endpoint considering 50% of growth inhibition. The number in parentheses shows how many times (X) the MIC value of the PCT-adapted or 10p colonies was higher ($\geq 4X$) than the MIC of the NA colonies. Values in bold indicate an increase in the MIC by at least 4X more than in the NA colonies. ND = not determined.

Table 6. Minimum inhibitory concentrations (MICs.mg/L) of fluconazole and pyraclostrobin for non-adapted (NA) cells of *C. gattii* and *C. neoformans* strains.PCT-adapted (A) at 35°C and PCT-adapted colonies subcultured 10 times in agrochemical-free medium (10p - 10 passages). Tests were performed at 35°C.

Strain or parameter	Fluconazole ^a			Pyraclostrobin ^b		
	NA	A	10p	NA	A	10p
<i>C. gattii</i>						
R265	8.0	8.0	ND	0.5	1.0	ND
ATCC 24065	4.0	4.0	ND	0.125	0.25	ND
ATCC 32608	8.0	8.0	ND	1.0	1.0	ND
547/OTTI/94-PI-10	8.0	16.0	ND	1.0	2.0	ND
ICB 181	8.0	8.0	ND	0.25	1.0 (4X)	0.5
L24/01	8.0	16.0	ND	0.25	0.25	ND
L27/01	32.0	16.0	ND	2.0	8.0 (4X)	8.0 (4X)
L28/02	16.0	16.0	ND	0.5	1.0	ND
1913/ER	16.0	16.0	ND	1.0	2.0	ND
LMM 818	16.0	8.0	ND	2.0	4.0	ND
23/10893	8.0	4.0	ND	4.0	8.0	ND
29/10933	4.0	4.0	ND	4.0	2.0	ND
MIC range	4.0 – 32.0	4.0 – 16.0	ND	0.125 – 4.0	0.25 – 8.0	ND
Geometric mean	9.51	8.97	ND	0.84	1.49	ND
<i>C. neoformans</i>						
H99	8.0	16.0	ND	0.5	0.5	ND
ATCC 24067	4.0	8.0	ND	1.0	16.0 (16X)	4.0 (4X)
ATCC 28957	2.0	4.0	ND	0.25	0.5	ND
ATCC 62066	4.0	4.0	ND	1.0	1.0	ND
MIC range	2.0 – 8.0	4.0 – 16.0	ND	0.25 – 1.0	0.5 – 16.0	ND
Geometric mean	4.0	6.72	ND	0.59	1.41	ND

a: MIC endpoint considering 50% of growth inhibition; *b*: MIC endpoint considering 100% of growth inhibition. The number in parentheses shows how many times (X) the MIC value of the PCT-adapted or 10p colonies was higher ($\geq 4X$) than the MIC of the NA colonies. Values highlighted indicate an increase in the MIC by at least 4X more than in the NA colonies. ND = not determined.

Table 7. List of down-regulated genes involved in ion metabolism and up-regulated genes that could be involved in drug resistance of *C. gattii* R265 10p cells.

ORF	Genes identification	Function	10p/NA Fold change
<i>CNBG_0560</i>	Solute carrier family 31 (copper transporter), member 1(<i>CTR4</i>)	Copper ion transmembrane transport	-2.45
<i>CNBG_6082</i>	Ferric-chelate reductase 7 (<i>FRE7</i>)	Oxidoreductase activity	-1.92
<i>CNBG_9038</i>	Ferric-chelate reductase	Oxidoreductase activity	-1.62
<i>CNBG_2627</i>	Ferric-chelate reductase 1 (<i>FRE1</i>)	Oxidoreductase activity	-1.62
<i>CNBG_4400</i>	Cytochrome b2, mitochondrial (<i>cytb</i>)	Respiration (target of pyraclostrobin)	2.058
<i>CNBG_1200</i>	ATP-binding cassette transporter (<i>AFR-1</i>)	Drug transport	1.566
<i>CNBG_1138</i>	Putative abc multidrug resistance transporter with similarity to Ste6 (<i>MDR11</i>)	Drug transport	1.526




Figure 1: Transcriptomic profile of *C. gattii* R265 10p cells is different from that of NA cells.. Function of genes up- (A) and down-regulated in 10p cells compared to NA.




Figure 2: Virulence and *in vivo* Cross-resistance in non-adapted (NA) and adapted cells subcultivated in medium without agrochemical (10p). A) 10p cells are significantly ($p < 0.05$) less virulent than NA. The treatment with fluconazole (FLC) significantly ($p < 0.05$) increased the survival of mice infected with NA, but not of those infected with 10p cells. B) Cells recovered from the lungs of animals infected with 10p colonies were more resistant to pyraclostrobin (PCT), fluconazole (FLC), itraconazole (ITZ) and ravuconazole (RVZ), but not to amphotericin B (AMB), than those recovered from NA-infected mice. ($p > 0.05$). * $p < 0.05$; ** $p < 0.01$ compared to NA group.